Note 4 - Acquisition of Grace (Tables)

12 Months Ended

Mar. 31, 2022

Notes To Financial Statements [Abstract]

Schedule of Business Acquisitions by Acquisition, Contingent Consideration

Total common shares issued		18,241,233
Acasti share price (closing share price on August 27, 2021)	$	3.3344
Fair value of common shares issued	$	60,824

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes the final fair value of assets acquired and liabilities assumed as of the acquisition date:

	$
Assets acquired and liabilities assumed
Cash and equivalents		90
Prepaid expenses and other current assets		74
Intangible assets – in-process research and development		69,810
Goodwill		12,964
Accounts payable and accrued expenses		(4,578	)
Deferred tax liability		(17,536	)
Total assets acquired and liabilities assumed		60,824

Schedule of Intangible Assets in Process Research and Development

Intangible assets of $69,810 relate to the value of IPR&D, related to Grace’s therapeutic pipeline, consisting of three unique clinical stage programs/assets supported by intellectual property, the value of which has been attributed as follows:

	$
Intangible assets – in-process research and development
GTX 104		27,595
GTX 102		31,908
GTX 101		10,307
Total		69,810

Business Acquisition, Pro Forma Information

	Year ended March 31, 2022
	$
Net loss		(13,734	)